HOOKIPA Pharma Earnings Call Transcripts
Fiscal Year 2024
-
Eservivec (HB-200) is advancing toward a pivotal trial with strong phase 2 data and FDA support, targeting approval in 2027 and potential standard-of-care status for head and neck cancer. Financial focus is on HB-200, with other programs seeking partnerships.
-
The meeting, held virtually for global access, saw all proposals—including director elections, auditor ratification, an increase in authorized shares, and a reverse stock split—overwhelmingly approved by shareholders. Final results will be reported in SEC filings.
-
HB-200 plus pembrolizumab demonstrated strong efficacy and durability in HPV-16 positive head and neck cancer, especially in the CPS 20+ subgroup, with a pivotal phase II/III trial set to start in Q4 2024. Regulatory alignment and market expansion plans are in place.